Context Therapeutics Announces Phase 1 Trial of CTIM-76 for Advanced Solid Tumors at 2025 ASCO Meeting

Reuters

06/02

Context <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Phase 1 Trial of CTIM-76 for Advanced Solid Tumors at 2025 ASCO Meeting

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the presentation of a Trial in Progress poster for its Phase 1 clinical trial of CTIM-76 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial focuses on CTIM-76, a Claudin 6 x CD3 T cell engager, and is being evaluated for its safety and efficacy in treating CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers. The study, which began dosing its first patient in January 2025, is currently in the dosing cohort 3 phase. It is an open-label, dose escalation and expansion study expected to enroll up to 70 patients. The company plans to share initial data in the first half of 2026. Presentation materials will be available on Context Therapeutics' website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461415-en) on June 02, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2540035767"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540035767\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540035767?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540035767","market":"us","top_or_hot":-1,"title":"Context Therapeutics Announces Phase 1 Trial of CTIM-76 for Advanced Solid Tumors at 2025 ASCO Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Context <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Phase 1 Trial of CTIM-76 for Advanced Solid Tumors at 2025 ASCO Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CNTX\">Context Therapeutics Inc.</a>, a clinical-stage biopharmaceutical company, has announced the presentation of a Trial in Progress poster for its Phase 1 clinical trial of CTIM-76 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial focuses on CTIM-76, a Claudin 6 x CD3 T cell engager, and is being evaluated for its safety and efficacy in treating CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers. The study, which began dosing its first patient in January 2025, is currently in the dosing cohort 3 phase. It is an open-label, dose escalation and expansion study expected to enroll up to 70 patients. The company plans to share initial data in the first half of 2026. Presentation materials will be available on Context Therapeutics' website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461415-en) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Context Therapeutics Announces Phase 1 Trial of CTIM-76 for Advanced Solid Tumors at 2025 ASCO Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nContext Therapeutics Announces Phase 1 Trial of CTIM-76 for Advanced Solid Tumors at 2025 ASCO Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-02 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Context <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Phase 1 Trial of CTIM-76 for Advanced Solid Tumors at 2025 ASCO Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CNTX\">Context Therapeutics Inc.</a>, a clinical-stage biopharmaceutical company, has announced the presentation of a Trial in Progress poster for its Phase 1 clinical trial of CTIM-76 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial focuses on CTIM-76, a Claudin 6 x CD3 T cell engager, and is being evaluated for its safety and efficacy in treating CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers. The study, which began dosing its first patient in January 2025, is currently in the dosing cohort 3 phase. It is an open-label, dose escalation and expansion study expected to enroll up to 70 patients. The company plans to share initial data in the first half of 2026. Presentation materials will be available on Context Therapeutics' website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461415-en) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL2dlCsc:1","article_id":"2540035767","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540035767","pubTimestamp":1748863851,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Context Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the presentation of a Trial in Progress poster for its Phase 1 clinical trial of CTIM-76 at the 2025 American Society of Clinical Oncology  Annual Meeting. The trial focuses on CTIM-76, a Claudin 6 x CD3 T cell engager, and is being evaluated for its safety and efficacy in treating CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers. The study, which began dosing its first patient in January 2025, is currently in the dosing cohort 3 phase. It is an open-label, dose escalation and expansion study expected to enroll up to 70 patients. The company plans to share initial data in the first half of 2026. Presentation materials will be available on Context Therapeutics' website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","CNTX":"Context Therapeutics Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Context Therapeutics在2025年ASCO会议上宣布CTIM-76治疗晚期实体瘤的1期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTX":0.9,"NDAQ":0.9},"content_text":"Context Therapeutics Announces Phase 1 Trial of CTIM-76 for Advanced Solid Tumors at 2025 ASCO Meeting\n    \n\nContext Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the presentation of a Trial in Progress poster for its Phase 1 clinical trial of CTIM-76 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial focuses on CTIM-76, a Claudin 6 x CD3 T cell engager, and is being evaluated for its safety and efficacy in treating CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers. The study, which began dosing its first patient in January 2025, is currently in the dosing cohort 3 phase. It is an open-label, dose escalation and expansion study expected to enroll up to 70 patients. The company plans to share initial data in the first half of 2026. Presentation materials will be available on Context Therapeutics' website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461415-en) on June 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}